Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 150.00
Bid: 140.00
Ask: 160.00
Change: 0.00 (0.00%)
Spread: 20.00 (14.286%)
Open: 150.00
High: 150.00
Low: 150.00
Prev. Close: 150.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holdings in Company

22 Jun 2018 07:00

RNS Number : 2122S
Faron Pharmaceuticals Oy
22 June 2018
 

TR-1: Standard form for notification of major holdings

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Faron Pharmaceuticals Oy7437009H31TO1DC0EB42

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii: Disclosure as per company's Articles of Association

X

3. Details of person subject to the notification obligationiv

Name

 

Legal & General Group Plc (Group)

 

Legal & General Investment Management Limited (LGIM)

 

Legal & General (Unit Trust Managers) Limited

 

City and country of registered office (if applicable)

1 Coleman St, London EC2R 5AA

4. Full name of shareholder(s) (if different from 3.)v

Name

Legal & General Assurance Society (LGAS)

 

City and country of registered office (if applicable)

1 Coleman St, London EC2R 5AA

5. Date on which the threshold was crossed or reachedvi:

19 June 2018

6. Date on which issuer notified (DD/MM/YYYY):

 

21 June 2018

 

 

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached (LGIM)

0.37%

-

0.37%

 

31,027,894

 

Position of previous notification (if

applicable) (LGIM)

1.53%

-

1.53%

Resulting situation on the date on which threshold was crossed or reached (UTM)

0.30%

-

0.30%

 

31,027,894

 

Position of previous notification (if

applicable) (UTM)

1.26%

-

1.26%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

ORD NPV

-

116,000

-

0.37%

SUBTOTAL 8. A

116,000

0.37%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

 

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

x

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

Legal & General Group (Direct/Indirect)

0.37%

0.37%

 

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

0.37%

0.37%

 

Legal & General Assurance Society (Direct)

0.06%

0.06%

 

 

Legal & General Group (Direct/Indirect)

0.37%

0.37%

 

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

0.37%

0.37%

Legal & General Assurance (Pensions Management) Limited

(Direct)

-

-

Legal & General Group (Direct/Indirect)

0.37%

0.37%

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

0.37%

0.37%

Legal & General Investment Management Limited (Indirect)

0.37%

0.37%

Legal & General Group (Direct/Indirect)

0.37%

0.37%

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

0.37%

0.37%

Legal & General (Unit Trust Managers) Limited (Indirect)

0.31%

0.31%

Legal & General Group (Direct/Indirect)

0.37%

0.37%

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

0.37%

0.37%

Go ETF Solutions

-

-

 

10. In case of proxy voting, please identify:

 

Name of the proxy holder

N/A

 

The number and % of voting rights held

N/A

 

The date until which the voting rights will be held

N/A

 

 

 

 

11. Additional informationxvi

 

 

Notification using the total voting rights figure of 31,027,894

 

 

Place of completion

Brunel House, 2 Fitzalan Road, Cardiff, CF24 0EB

Date of completion

21/06/2018

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLLFLLLVQFXBBZ
Date   Source Headline
6th Nov 20183:52 pmRNSPDMR Dealings
23rd Oct 201811:05 amRNSSecond Price Monitoring Extn
23rd Oct 201811:00 amRNSPrice Monitoring Extension
23rd Oct 20189:06 amRNSSecond Price Monitoring Extn
23rd Oct 20189:00 amRNSPrice Monitoring Extension
22nd Oct 20183:00 pmRNSINTEREST trial update presented at ESICM
18th Sep 20189:23 amRNSDirector/PDMR Shareholding
17th Sep 20187:00 amRNSFaron announces CTA filing for Clevegen
13th Sep 20187:00 amRNSInterim Results
12th Sep 20187:00 amRNSNew data published on Clever-1 function
8th Aug 201811:05 amRNSSecond Price Monitoring Extn
8th Aug 201811:00 amRNSPrice Monitoring Extension
8th Aug 20187:00 amRNSNotice of Interim Results
9th Jul 20188:45 amRNSHolding(s) in Company
28th Jun 20187:00 amRNSClevegen successful toxicity studies
22nd Jun 20187:00 amRNSHoldings in Company
21st Jun 20183:58 pmRNSDirector/PDMR Shareholding
21st Jun 20189:00 amRNSPrice Monitoring Extension
21st Jun 20187:40 amRNSDirector/PDMR Shareholding
20th Jun 20182:05 pmRNSSecond Price Monitoring Extn
20th Jun 20182:00 pmRNSPrice Monitoring Extension
20th Jun 20188:43 amRNSHolding(s) in Company
18th Jun 20183:42 pmRNSHoldings in Company
15th Jun 20184:40 pmRNSSecond Price Monitoring Extn
15th Jun 20184:35 pmRNSPrice Monitoring Extension
14th Jun 201811:05 amRNSSecond Price Monitoring Extn
14th Jun 201811:00 amRNSPrice Monitoring Extension
14th Jun 20187:00 amRNSBiomarker analysis of Phase III INTEREST trial
31st May 20182:33 pmRNSResult of AGM
31st May 20187:00 amRNSAGM Statement
16th May 20185:53 pmRNSPDMR Shareholding
15th May 20183:14 pmRNSDirector/PDMR Shareholding
15th May 20182:05 pmRNSSecond Price Monitoring Extn
15th May 20182:00 pmRNSPrice Monitoring Extension
15th May 20181:16 pmRNSHoldings in Company
11th May 20184:51 pmRNSHolding(s) in Company
11th May 20181:37 pmRNSHolding(s) in Company
11th May 20181:34 pmRNSHolding(s) in Company
11th May 20187:00 amRNSUpdate on the Phase III INTEREST trial
10th May 201810:05 amRNSNotice of AGM
9th May 20184:40 pmRNSSecond Price Monitoring Extn
9th May 20184:35 pmRNSPrice Monitoring Extension
9th May 201812:54 pmRNSHoldings in Company
8th May 20189:05 amRNSSecond Price Monitoring Extn
8th May 20189:00 amRNSPrice Monitoring Extension
8th May 20187:00 amRNSTop line data from the Phase III INTEREST trial
8th May 20187:00 amRNSFinal Results for the year ended 31 December 2017
25th Apr 201812:43 pmRNSHoldings in Company
21st Mar 20187:00 amRNSNotice of Full Year Results
6th Mar 201812:54 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.